{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:16:20Z","timestamp":1778242580833,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.eimce.2026.503146","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:06:07Z","timestamp":1778241967000},"page":"503146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SARS-CoV-2 spike-directed T cells and anti-receptor-binding-domain antibodies in hematological patients receiving three mRNA COVID-19 vaccine doses"],"prefix":"10.1016","volume":"44","author":[{"given":"Diego","family":"Carretero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estela","family":"Gim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadna","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Hernani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Pi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliseo","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimce.2026.503146_bib0215","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.eimce.2026.503146_bib0220","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41375-021-01302-5","article-title":"COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey","volume":"35","author":"Ljungman","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.eimce.2026.503146_bib0225","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","article-title":"Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.eimce.2026.503146_bib0230","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.cmi.2022.10.030","article-title":"B-cell malignancies and COVID-19: a narrative review","volume":"29","author":"Luque-Paz","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"suppl 1","key":"10.1016\/j.eimce.2026.503146_bib0235","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1093\/infdis\/jiad174","article-title":"COVID-19 vaccination in patients with cancer and patients receiving HSCT or CAR-T therapy: immune response, real-world effectiveness, and implications for the future","volume":"228","author":"Hall","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimce.2026.503146_bib0240","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cmi.2021.09.036","article-title":"Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review","volume":"28","author":"Galmiche","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimce.2026.503146_bib0245","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.ccell.2021.11.011","article-title":"Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients","volume":"39","author":"Harrington","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eimce.2026.503146_bib0250","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3390\/vaccines10030448","article-title":"SARS-CoV-2 T-cell responses in allogeneic hematopoietic stem cell recipients following two doses of BNT162b2 mRNA vaccine","volume":"10","author":"Cl\u00e9menceau","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.eimce.2026.503146_bib0255","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy \u2013 a single-center prospective cohort study","volume":"27","author":"Ram","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.eimce.2026.503146_bib0260","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/vaccines9101075","article-title":"Humoral and cellular vaccination responses against SARS-CoV-2 in hematopoietic stem cell transplant recipients","volume":"9","author":"Lindemann","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.eimce.2026.503146_bib0265","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bjh.18312","article-title":"Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant","volume":"198","author":"Murray","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eimce.2026.503146_bib0270","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/cancers14061544","volume":"14","author":"Jotschke","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eimce.2026.503146_bib0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105385","article-title":"Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID","volume":"109","author":"Chen","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.eimce.2026.503146_bib0280","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3390\/vaccines12090961","article-title":"SARS-CoV-2-specific T lymphocytes analysis in mRNA-vaccinated patients with B-cell lymphoid malignancies on active treatment","volume":"12","author":"Garc\u00eda Ram\u00edrez","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.eimce.2026.503146_bib0285","doi-asserted-by":"crossref","first-page":"e920","DOI":"10.1093\/cid\/ciab930","article-title":"Severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines in allogeneic hematopoietic stem cell transplant recipients: immunogenicity and reactogenicity","volume":"75","author":"Sherman","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2026.503146_bib0290","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41408-022-00776-5","article-title":"Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis","volume":"12","author":"Uaprasert","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.eimce.2026.503146_bib0295","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.3324\/haematol.2021.280163","article-title":"Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis","volume":"107","author":"Gagelmann","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.eimce.2026.503146_bib0300","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1182\/bloodadvances.2021006333","article-title":"Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis","volume":"6","author":"Teh","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.eimce.2026.503146_bib0305","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2022.3227","article-title":"Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19","volume":"8","author":"Haggenburg","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eimce.2026.503146_bib0310","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41375-023-01938-5","article-title":"Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)","volume":"37","author":"Cesaro","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.eimce.2026.503146_bib0315","article-title":"Safety and immunogenicity after a three-dose SARS-CoV-2 vaccine schedule in allogeneic stem cell transplant recipients","volume":"28","author":"Kimura","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.eimce.2026.503146_bib0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.05.081","article-title":"Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series","volume":"42","author":"Sherman","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.eimce.2026.503146_bib0325","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/bjh.18962","article-title":"Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination","volume":"202","author":"Pinder","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eimce.2026.503146_bib0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126547","article-title":"Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer","volume":"46","author":"Body","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.eimce.2026.503146_bib0335","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/ajh.27218","article-title":"Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: a study by ERIC, the European Research Initiative on CLL","volume":"99","author":"Campanella","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.eimce.2026.503146_bib0340","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/infdis\/jiad511","article-title":"Prospective assessment of humoral and cellular immune responses to a third COVID-19 mRNA vaccine dose among immunocompromised individuals","volume":"229","author":"Haidar","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimce.2026.503146_bib0345","doi-asserted-by":"crossref","first-page":"101017","DOI":"10.1016\/j.xcrm.2023.101017","article-title":"Robust SARS-CoV-2 T cell responses with common TCR\u03b1\u03b2 motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells","volume":"4","author":"Nguyen","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.eimce.2026.503146_bib0350","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.vaccine.2023.01.064","article-title":"Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies","volume":"41","author":"Gressens","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.eimce.2026.503146_bib0355","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/2643-3230.BCD-22-0173","article-title":"Impaired SARS-CoV-2 variant neutralization and CD8+ T-cell responses following 3 doses of mRNA vaccines in myeloma: correlation with breakthrough infections","volume":"4","author":"Azeem","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.eimce.2026.503146_bib0360","article-title":"Immunogenicity and safety of booster SARS-CoV-2 mRNA vaccine dose in allogeneic hematopoietic stem cell transplantation recipients","volume":"29","author":"Mittal","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.eimce.2026.503146_bib0365","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ccell.2022.01.010","article-title":"Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients","volume":"40","author":"Sesques","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eimce.2026.503146_bib0370","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41467-022-28578-0","article-title":"Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies","volume":"13","author":"Re","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.eimce.2026.503146_bib0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107347","article-title":"mRNA-1273 SARS-CoV-2 vaccine in recently transplanted allogeneic hematopoietic cell transplant recipients: dynamics of cellular and humoral immune responses and booster effect","volume":"132","author":"Albiol","year":"2023","journal-title":"Leuk Res"},{"key":"10.1016\/j.eimce.2026.503146_bib0380","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14003","article-title":"Antibody, cell-mediated response and infection susceptibility in allogeneic hematopoietic stem cell recipients after COVID-19 mRNA vaccination","volume":"25","author":"Pizzano","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.eimce.2026.503146_bib0385","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ccell.2022.02.010","article-title":"Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients","volume":"40","author":"Abid","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eimce.2026.503146_bib0390","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12985-024-02375-1","article-title":"Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis","volume":"21","author":"Sharifi Aliabadi","year":"2024","journal-title":"Virol J"},{"key":"10.1016\/j.eimce.2026.503146_bib0395","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/vaccines12070752","article-title":"Risk factors for impaired cellular or humoral immunity after three doses of SARS-CoV-2 vaccine in healthy and immunocompromised individuals","volume":"12","author":"Ko","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.eimce.2026.503146_bib0400","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29790","article-title":"SARS-CoV-2-Spike T-cell response after receiving one or two Wuhan-Hu-1-based mRNA COVID-19 vaccine booster doses in elderly nursing home residents","volume":"96","author":"Carretero","year":"2024","journal-title":"J Med Virol"},{"key":"10.1016\/j.eimce.2026.503146_bib0405","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjh.19221","article-title":"Increasing insight in the value of repetitive COVID-19 vaccination in patients with haematological malignancies in the Omicron era","volume":"204","author":"Bacher","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eimce.2026.503146_bib0410","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156559","article-title":"In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals","volume":"7","author":"Li","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.eimce.2026.503146_bib0415","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/infdis\/jiac421","article-title":"Antibody and T-Cell subsets analysis unveils an immune profile heterogeneity mediating long-term responses in individuals vaccinated against SARS-CoV-2","volume":"227","author":"Agallou","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimce.2026.503146_bib0420","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1272119","article-title":"A 12-month follow-up of the immune response to SARS-CoV-2 primary vaccination: evidence from a real-world study","volume":"14","author":"Fedele","year":"2023","journal-title":"Front Immunol"}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X26000766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X26000766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:07:06Z","timestamp":1778242026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X26000766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2529993X26000766"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2026.503146","relation":{},"ISSN":["2529-993X"],"issn-type":[{"value":"2529-993X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 spike-directed T cells and anti-receptor-binding-domain antibodies in hematological patients receiving three mRNA COVID-19 vaccine doses","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2026.503146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica.","name":"copyright","label":"Copyright"}],"article-number":"503146"}}